In our study cumulative APOA-I genetic variations (APOA-I GRS) decreased the risk of insulin resistance and MetS, whereas cumulative APOB genetic variations (APOB GRS) increased the risk of MetS in OSA. Here, APOB is linked to metabolic syndrome.